Of rats and men: Superwarfarin toxicity

Lancet

Volumn 365, Issue 9459, 2005, Pages 552-554

  Sharma, Pankaj ^a   Bentley, Paul ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRODIFACOUM; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOTOXICITY; DRUG EFFECT; DRUG INTOXICATION; HUMAN; LIVER TOXICITY; NOTE; PRIORITY JOURNAL; VITAMIN METABOLISM;

EID: 13844275420     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70773-X     Document Type: Note

References (15)

1. Montefiore SS. Stalin-the court of the red tsar. 2nd impression. London: Phoenix, Orion Books, 2004.
2. Pelfrene AF. Synthetic organic rodenticides. In: Hayes WJ Jr, Laws ER Jr. Handbook of pesticide toxicology. San Diego: Academic Press, 1991.
3. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med. 45:2005;197-206
4. Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med. 158:1998;1929-1932
5. Martin-Bouyer G, Khan NB, Linh PD, et al. Epidemic of haemorrhagic disease in Vietnamese infants caused by warfarin-contaminated talc. Lancet. 1:1983;230-232
6. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:2001;8S-21S
7. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 354:1999;1457-1463
8. Sam C, Massaro JM, D'Agostino Sr RB, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 94:2004;947-951
9. News in brief. Setback for anticoagulant drug. Nat Rev Drug Disc. 3:2004;819
10. Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor Ixa. Nature. 419:2002;90-94
11. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 103:2004;2630-2635
12. D'Andrea G, D'Ambrosio RL, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 105:2005;645-649
13. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 427:2004;537-541
14. Hart RG. What causes intracerebral hemorrhage during warfarin therapy? Neurology. 55:2000;907-908
15. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 79:2004;1495-1500